IMCR — Immunocore Holdings Share News
0.000.00%
Last trade - 00:00- $1.54bn
- $1.05bn
- $400.02m
Brief: Immunocore Announces Dosing Of First Patient With ImmTAV Bispecific For HIV
Brief: Medison Pharma Announces Approvals By Health Canada And Therapeutics Goods Administration Of Kimmtrak® (Tebentafusp) For Treatment Of Unresectable Or Metastatic Uveal Melanoma
Brief: Immunocore Says UK, Australia And Canada Approve Kimmtrak For Treatment Of Unresectable Or Metastatic Uveal Melanoma
Brief: Immunocore Presents New Data On Cancer Treatment At Annual Oncology Conference
Brief: Immunocore Announces Clinical Trial Collaboration With Sanofi To Evaluate Sanofi’ Sar444245 With Kimmtrak® In Patients With Metastatic Cutaneous Melanoma
Brief: Immunocore Announces Upcoming Presentations
Brief: Medison Pharma Announces Extension Of Multi-Territorial Agreement With Immunocore
Brief: Immunocore Reports First Quarter 2022 Financial Results And Provides Business Update
Immunocore Holdings rises on EU approval of cancer therapy
Brief: European Commission Approves Kimmtrak For Treatment Of Unresectable Or Metastatic Uveal Melanoma
Brief: Immunocore Reports Full Year 2021 Financial Results And Provides Business Update
Immunocore Holdings jumps on FDA approval of cancer drug
U.S. STOCKS ON THE MOVE-JinkoSolar, Tyme Technologies, Texas Instruments
Brief: Immunocore Announces FDA Approval Of KIMMTRAK® (tebentafusp-tebn) For The Treatment Of Unresectable Or Metastatic Uveal Melanoma
Brief: Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
Brief: Immunocore Reports Third Quarter 2021 Financial Results
Brief: Immunocore And Medison Pharma Partner For Future Commercialization Of Tebentafusp In Canada, Central Eastern Europe, And Israel
Brief: Immunocore Announces Publication Of Phase 3 Data Comparing Tebentafusp With Investigator’s Choice
Brief: Immunocore Presents New Data From Its Phase 2 Clinical Trial Of Tebentafusp At The ESMO Congress 2021